Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP.

Autores de IIS La Fe

• Ester Donat Aliaga

  Autor

Participantes ajenos a IIS La Fe

• Velasco Rodriguez-Belvis, Marta
• Palomino, Laura
• Pujol-Muncunill, Gemma
• Martin-Masot, Rafael
• Medina Benitez, Enrique
• Fernandez-Lorenzo, Ana Estefania
• Moreno-Alvarez, Ana
• Molina Arias, Manuel
• Hidalgo Montes, Inmaculada
• Navas-Lopez, Victor Manuel
• Martin de Carpi, Javier
• Lozano Ruf, Ana
• Blasco-Alonso, Javier
• Barrio Torres, Josefa
• Montraveta, Montserrat
• Pena-Quintana, Luis
• Ramos Rueda, Natalia
• Rodriguez Martinez, Alejandro
• Botija Arcos, Gonzalo
• Alonso Vicente, Carmen
• Castro Millan, Ana Maria
• Fernandez Cebrian, Santiago
• Sanchez Sanchez, Cesar
• Loverdos, Ines
• Segarra Canton, Oscar
• Ruiz Castellano, Noelia
• Torres-Peral, Ricardo
• Crehua-Gaudiza, Elena
• Millan Jimenez, Antonio
• Jovani Casano, Carmen
• Vicente Santamaria, Saioa
• Tabares Gonzalez, Ana
• Garcia-Romero, Ruth
• Ros Arnal, Ignacio
• Balboa Vega, Maria Jesus
• Escartin Madurga, Laura
• Martinon Torres, Nazareth
• Crujeiras Martinez, Vanesa
• Gonzalez-Vives, Leticia
• Perez-Moneo, Begona
• Masiques Mas, Maria Lluisa
• Vegas Alvarez, Ana Maria
• Grande Herrero, Luis
• La Orden Izquierdo, Enrique
• Chicano Marin, Francisco Jose
• de Las Mercedes Busto Cuinas, Maria
• Martinez de Zabarte Fernandez, Jose Miguel
• Alberto Alonso, Jose Ramon
• Andres Esteban, Eva Maria

Grupos

• Enfermedad celíaca e Inmunopatología digestiva

Abstract

IMPACT-III and IMPACT-III-P are health-related quality of life (HRQoL) questionnaires for patients with pediatric inflammatory bowel disease (p-IBD) and their parents/caregivers. We aimed to perform a transcultural adaptation and validation for the Spanish context. Translation, back-translation, and evaluation of the questionnaires were performed by an expert committee and 12 p-IBD families. We recruited p-IBD patients aged 10-17 and their parents/caregivers. Utility, content, and face validity were considered. Validation was performed with Cronbach's alpha coefficient and varimax rotation. We confirmed the adequacy of the factor analysis using Kaiser-Meyer-Olkin (KMO) and Bartlett's sphericity tests. A confirmatory factor analysis was performed using the following goodness indexes: chi-square, Normed Fit Index (NFI), Root Mean Square Error of Approximation index (RMSEA), Standardized Root Mean Square Residual (SRMR), and Comparative Fit Index (CFI). The correlation coefficient between IMPACT-III and IMPACT-III-P was analyzed. We included 370 patients and 356 parents/caregivers (37 hospitals). Both questionnaires had good content and face validity and were considered user-friendly. The KMO measure (0.8998 and 0.9228, respectively) and Bartlett's sphericity test (p-value<0.001 for both) confirmed the adequacy of the factor analysis. The 4-factor model, complying with Kaiser's criterion, explained 89.19% and 88.87% of the variance. Cronbach's alpha (0.9123 and 0.9383) indicated excellent internal consistency. The CFA showed an adequate fit (NFI 0.941 and 0.918, RMSEA 0.048 and 0.053, SRMR 0.037 and 0.044, and CFI 0.879 and 0.913). The correlation coefficient was excellent (0.92). CONCLUSION: The SEGHNP versions of IMPACT-III and IMPACT-III-P are valid and reliable instruments for Spanish p-IBD families. WHAT IS KNOWN: IMPACT-III and parent-proxy IMPACT-III (IMPACT-III-P) are useful questionnaires for assessing health-related quality of life (HRQoL) in pediatric inflammatory bowel disease (p-IBD) patients and their parents/caregivers and have been translated and validated in several countries. To date, no transcultural adaptation and validation of these questionnaires have been published for Spanish patients with p-IBD and their families. WHAT IS NEW: This is the first transcultural adaptation and validation of IMPACT-III and IMPACT-III-P for Spanish p-IBD families. These are valid and reliable instruments for assessing HRQoL in Spanish families of patients with p-IBD.

Keywords

• Pediatric inflammatory bowel disease (p-IBD); Health-related quality of life (HRQoL); Questionnaires; Validation